{"filing":{"accession_number":"0001493152-26-032694","cik":"0001419554","ticker":"BBLGW","company_name":"Bone Biologics Corp","form":"8-K","filing_date":"2026-07-09","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1419554/000149315226032694/form8-k.htm"},"events":[{"id":16878,"run_id":15102,"accession_number":"0001493152-26-032694","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Bone Biologics priced a private offering on July 7, 2026, selling pre-funded warrants and Series F and G warrants to purchase 2,112,677 shares of common stock at a combined purchase price of $1.419 per unit, generating approximately $2.7 million in net proceeds with potential additional gross proceeds of approximately $6 million upon full exercise of the warrants. The securities were issued without registration under Section 4(a)(2) of the Securities Act as a private placement to an accredited investor.","company_name":"Bone Biologics Corp","ticker":"BBLGW","filing_date":"2026-07-09","form":"8-K","submitted_at":null,"items":[{"id":15110,"accession_number":"0001493152-26-032694","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Bone Biologics priced a private offering on July 7, 2026, selling pre-funded warrants and Series F and G warrants to purchase 2,112,677 shares of common stock at a combined purchase price of $1.419 per unit, generating approximately $2.7 million in net proceeds. The securities were issued without registration under Section 4(a)(2) of the Securities Act as a private placement to an accredited investor, with potential additional gross proceeds of approximately $6 million upon full exercise of the warrants. This is a classic dilutive equity issuance raising capital through unregistered warrant and pre-funded warrant sales.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:46:18.190968+00:00","company_name":"","ticker":null,"filing_date":""},{"id":15111,"accession_number":"0001493152-26-032694","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Bone Biologics announced a private placement of 2,112,677 shares of common stock (or pre-funded warrants) at $1.42 per share, generating $3.0 million upfront with up to $6.0 million in additional potential proceeds from warrant exercises. The securities are unregistered and offered under Section 4(a)(2) of the Securities Act and Regulation D, which is the hallmark of a dilutive private equity issuance. This is a material capital-raising event for a small-cap biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:46:18.190968+00:00","company_name":"","ticker":null,"filing_date":""},{"id":15112,"accession_number":"0001493152-26-032694","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Bone Biologics announced a private placement of 2,112,677 shares of common stock (or pre-funded warrants) plus Series F and Series G warrants for $1.42 per share, raising approximately $3.0 million upfront with up to $6.0 million in potential additional proceeds. This is a classic unregistered equity issuance under Section 4(a)(2) and Regulation D, structured as a PIPE-like transaction with warrants. The dilutive nature and capital-raising purpose are material to investors assessing the registrant's equity structure and financing strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:46:18.190968+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15110,"accession_number":"0001493152-26-032694","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Bone Biologics priced a private offering on July 7, 2026, selling pre-funded warrants and Series F and G warrants to purchase 2,112,677 shares of common stock at a combined purchase price of $1.419 per unit, generating approximately $2.7 million in net proceeds. The securities were issued without registration under Section 4(a)(2) of the Securities Act as a private placement to an accredited investor, with potential additional gross proceeds of approximately $6 million upon full exercise of the warrants. This is a classic dilutive equity issuance raising capital through unregistered warrant and pre-funded warrant sales.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:46:18.190968+00:00","company_name":"Bone Biologics Corp","ticker":"BBLGW","filing_date":"2026-07-09"},{"id":15111,"accession_number":"0001493152-26-032694","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Bone Biologics announced a private placement of 2,112,677 shares of common stock (or pre-funded warrants) at $1.42 per share, generating $3.0 million upfront with up to $6.0 million in additional potential proceeds from warrant exercises. The securities are unregistered and offered under Section 4(a)(2) of the Securities Act and Regulation D, which is the hallmark of a dilutive private equity issuance. This is a material capital-raising event for a small-cap biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:46:18.190968+00:00","company_name":"Bone Biologics Corp","ticker":"BBLGW","filing_date":"2026-07-09"},{"id":15112,"accession_number":"0001493152-26-032694","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Bone Biologics announced a private placement of 2,112,677 shares of common stock (or pre-funded warrants) plus Series F and Series G warrants for $1.42 per share, raising approximately $3.0 million upfront with up to $6.0 million in potential additional proceeds. This is a classic unregistered equity issuance under Section 4(a)(2) and Regulation D, structured as a PIPE-like transaction with warrants. The dilutive nature and capital-raising purpose are material to investors assessing the registrant's equity structure and financing strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:46:18.190968+00:00","company_name":"Bone Biologics Corp","ticker":"BBLGW","filing_date":"2026-07-09"}]}